This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/resource/domain/vavai/subjekt/
n5http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F12%3A12948%21RIV13-MZ0-00064165/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F12%3A12948%21RIV13-MZ0-00064165
rdf:type
skos:Concept n5:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.3324/haematol.2011.056176
dcterms:description
The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or break-apart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance. The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or break-apart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.
dcterms:title
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
skos:prefLabel
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
skos:notation
RIV/00064165:_____/12:12948!RIV13-MZ0-00064165
n5:predkladatel
n6:ico%3A00064165
n3:aktivita
n4:V n4:I
n3:aktivity
I, V
n3:cisloPeriodika
8
n3:dodaniDat
n14:2013
n3:domaciTvurceVysledku
n11:7529805 n11:1129244
n3:druhVysledku
n13:J
n3:duvernostUdaju
n10:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
165049
n3:idVysledku
RIV/00064165:_____/12:12948
n3:jazykVysledku
n16:eng
n3:klicovaSlova
myeloma; cytogenetic; interphase FISH; recommendation
n3:klicoveSlovo
n12:recommendation n12:cytogenetic n12:interphase%20FISH n12:myeloma
n3:kodStatuVydavatele
IT - Italská republika
n3:kontrolniKodProRIV
[6A2C89490E75]
n3:nazevZdroje
Haematologica
n3:obor
n7:FD
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
30
n3:rokUplatneniVysledku
n14:2012
n3:svazekPeriodika
97
n3:tvurceVysledku
Bernasconi, P. Collin, A. Rack, K. Michau, L. Neben, K. Avet-Loiseau, H. Johnsen, HE Ladon, D. Kerndrup, G. Fabris, S. Ross, FM Sonneveld, P. O\'Connor, S. Hermansen, NEU Dalva, K. Kuglik, P. Gutierrez, NC Poirel, HA Nyegaard, M. Rocci, A. Testi, A. M. Chiecchio, L. Ameye, G. Zemanová, Zuzana Liebisch, P. Hodkinson, C. Jarosova, M. Michalová, Kyra Maes, B. Protheroe, R.
n3:wos
000307524100023
s:issn
0390-6078
s:numberOfPages
6